New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 16, 2013
10:04 EDTEFC, LOCM, TPRE, KIM, DDR, RGDO, MFA, WRI, REG, ECYT, BEAV, DX, SDLP, BFS, RPT, EVTC, AMRE, BMRNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AmREIT (AMRE) initiated with an Add at Capital One... BE Aerospace (BEAV) initiated with a Buy at Citigroup... DDR Corp. (DDR) initiated with an Add at Capital One... EVERTEC (EVTC) initiated with a Buy at BofA/Merrill... Endocyte (ECYT) initiated with a Buy at Brean Capital... Kimco Realty (KIM) initiated with a Strong Buy at Capital One... Ramco-Gershenson (RPT) initiated with a Neutral at Capital One... Regency Centers (REG) initiated with an Add at Capital One... Saul Centers (BFS) initiated with an Add at Capital One... Third Point Reinsurance (TPRE) initiated with a Buy at BofA/Merrill... Weingarten Realty (WRI) initiated with a Strong Buy at Capital One... Local (LOCM) initiated with a Buy at Merriman... Seadrill Partners (SDLP) coverage resumed with a Buy at Global Hunter... MFA Financial (MFA) initiated with a Buy at Compass Point... Ellington Financial (EFC) initiated with a Buy at Compass Point... Dynex Capital (DX) initiated with a Buy at Compass Point... Regado Biosciences (RGDO) initiated with an Outperform at Cowen... BioMarin (BMRN) reinstated with a Buy at BofA/Merrill.
News For AMRE;BEAV;DDR;EVTC;ECYT;KIM;RPT;REG;TPRE;BFS;WRI;LOCM;SDLP;MFA;EFC;DX;RGDO;BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 26, 2015
05:57 EDTBMRNBioMarin sees non-GAAP profitability in 2017 on drisapersen approval
BioMarin said in last night's earnings release, "The acquisition of Prosensa in January 2015 adds exciting potential products to our rare disease portfolio. Importantly for shareholders, we believe the near-term approval of drisapersen in either the U.S. or Europe will drive us to profitability on a non-GAAP basis in 2017."
05:56 EDTBMRNBioMarin sees NDA submission for drisapersen in April
Subscribe for More Information
February 25, 2015
16:13 EDTKIMKimco Realty CEO David Henry retiring, succeeded by COO Conor Flynn in 2016
Kimco Realty CEO David B. Henry will retire on January 1, 2016. Conor C. Flynn, President and COO, has been appointed to succeed Mr. Henry as CEO on that date. Conor Flynn was appointed President of the company in August 2014 after previously being named Kimco’s COO and, more recently, Chief Investment Officer. Mr. Flynn will continue in these roles until January 1, 2016.
16:12 EDTBMRNBioMarin sees 2015 revenue $840M-$870M, consensus $880.59M
On a constant currency basis, BioMarin revenue would have been between $885M-$915M. The company sees a 2015 GAAP loss ($360M)-($400M).
16:11 EDTBMRNBioMarin reports Q4 GAAP EPS (47c), consensus (59c)
Subscribe for More Information
15:05 EDTBMRNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include salesforce.com (CRM), consensus 14c... Avago Technologies (AVGO), consensus $1.94... L Brands (LB), consensus $1.80... Workday (WDAY), consensus (6c)... BioMarin (BMRN), consensus (59c)... Concho Resources (CXO), consensus 84c... Antero Resources (AR), consensus 28c... Medivation (MDVN), consensus $1.34... Transocean (RIG), consensus 77c... Sprouts Farmers Market (SFM), consensus 9c... SINA Corporation (SINA), consensus 18c.
06:14 EDTBMRNPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 23, 2015
16:27 EDTBMRNOn The Fly: Closing Wrap
Stocks on Wall Street began the session in negative territory and remained there for most of the session, with the Nasdaq the lone index to post a small gain. The Dow was weighed down by shares of Boeing (BA), which slid after the stock received a downgrade. There was little in the way of positive economic news, as the most notable report showed existing homes were lower than expected due to a shortage of inventory. The averages drifted for most of the session, as investors may be waiting on the sidelines ahead of tomorrow’s banking panel testimony by Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index rebounded to 0.13 in January, which was nearly in-line with expectations. Existing home sales dropped 4.9% to a 4.82M rate in January, which was much worse than the expected 1.8% drop to a 4.95M unit rate. In Europe, the Ifo Institute’s measure of German business confidence rose to 106.8 in February, which was up a tenth of a percentage point from the previous month but below the 107.7 consensus forecast. Also, the Bank of Israel became the latest central bank to cut rates this year, lowering its main interest rate to 0.1% from 0.25%. COMPANY NEWS: The shares of a number of health insurers rose after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for the insurers. Following the CMS announcement made late Friday, Humana (HUM) climbed $8.40, or 5.38%, to $164.52, UnitedHealth (UNH) rose $3.78, or 3.36%, to $116.40, and WellCare (WCG) gained $4.68, or 5.53%, to $89.30. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which jumped $9.77, or 17.7%, to $64.96 after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN). Also higher was Valeant (VRX), which rose $25.49, or 14.71%, to $198.75 after the company agreed to buy Salix (SLXP) for $158 per share and also reported better-than-forecast earnings. Salix shares, however, fell $2.09, or 1.32%, to $155.76, as a report Friday from CNBC's David Faber telegraphed the deal and suggested Valeant could value Salix around $160 per share. Among the noteworthy losers was Spectrum Pharmaceuticals (SPPI), which dropped $1.18, or 15.82%, to $6.28 after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. Also lower were shares of Boeing, which fell $3.57, or 2.26%, to $154.74 after the stock was downgraded to Sell from Neutral at Goldman Sachs. INDEXES: The Dow fell 23.60, or 0.13%, to 18,116.84, the Nasdaq gained 5.01, or 0.1%, to 4,960.97, and the S&P 500 slipped 0.64, or 0.03%, to 2,109.66.
12:29 EDTBMRNPTC Therapeutics exploring potential sale, Reuters reports
Subscribe for More Information
06:51 EDTBEAVAerospace sector downgraded to Neutral from Attractive at Goldman
Goldman downgraded the Aerospace sector to Neutral based on group outperformance and increased downside risks. The firm believes Boeing (BA) and Airbus are now oversupplying the market after a decade of undersupply and replacement demand required to sustain production may prove difficult to achieve. Goldman said accelerated new aircraft replacements was partially due to fuel economics and lower fuel prices and global growth volatility could substantially change Aerospace dynamics. As part of the sector view change, Goldman downgraded Boeing to Sell from Neutral and Precision Castparts (PCP) to Natural from Buy.
February 19, 2015
09:59 EDTWRIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
05:54 EDTWRIWeingarten Realty upgraded to Neutral from Sell at UBS
Subscribe for More Information
February 18, 2015
16:17 EDTEVTCEVERTEC reports Q4 EPS 44c, consensus 45c
Subscribe for More Information
February 17, 2015
10:00 EDTTPREOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:42 EDTTPREThird Point Reinsurance upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Third Point Reinsurance to Buy and other names in the Property and Casualty Insurance space saying the loss trend environment may remain muted through 2016. Citi raised its price target for shares to $17 from $16.
06:03 EDTWRIWeingarten Realty board increases dividend by 6.2% to 34.5c
Subscribe for More Information
06:02 EDTWRIWeingarten Realty reports acquisitions totaled $44M for the year
Reports dispositions totaled $166 million for the fourth quarter and $387 million for the year.
06:02 EDTWRIWeingarten Realty sees FY15 FFO $2.12-$2.17, consensus $2.12
Subscribe for More Information
06:01 EDTWRIWeingarten Realty reports Same property net operating income up 3.6% in Q4
Subscribe for More Information
06:01 EDTWRIWeingarten Realty reports Q4 FFO 51c, consensus 51c
Reports Q4 revenue $126.10M, consensus $126.05M
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use